T8641

Vancomycin is a glycopeptide antibiotic that exerts its antibacterial activity by inhibiting the second stage of cell wall synthesis in susceptible bacteria. It also alters cell membrane permeability and selectively inhibits RNA synthesis. Vancomycin is commonly used to treat severe infections resistant to other antibiotics and is frequently employed in experimental studies to induce kidney injury models.

FC14-584B, a dithiocarbamate and β-Carbonic Anhydrase inhibitor, impedes the growth of trophozoites and can be utilized for tuberculosis research [1].

Ferroptosis-IN-4 (compound 6k), an inhibitor of ferroptosis, exhibits an EC50 of 20 μM and lacks significant cytotoxicity. It demonstrates a protective role in glycerol-induced RM-AKI mice by alleviating kidney dysfunction [1].

Ferroptosis-IN-5 (compound 9c) acts as a ferroptosis inhibitor, boasting iron-chelating and reactive oxygen species (ROS) scavenging properties [1].

Ferroptosis-IN-6 is a potent ferroptosis inhibitor that protects cells from ferroptosis-induced cell death and inhibits STY-BODIPY oxidation. It is used in studies of ischemia-reperfusion injury.

Vancomycin-C13,D3 is a compound labeled with 13C and 2H. Vancomycin (T8641) is a glycopeptide antibiotic that exerts antibacterial activity by altering cell membrane permeability and selectively inhibiting RNA synthesis.